Asker Healthcare Group AB (SE:ASKER)
:ASKER
Want to see SE:ASKER full AI Analyst Report?
Top Page
Asker Healthcare Group AB
(ASKER)
Select Model
Select Model
Rating:62Neutral
Price Target:
kr89.00
â–²(8.21% Upside)
Action:Reiterated
Date:05/07/26
The score is driven mainly by strong revenue growth and improving profitability with positive free cash flow, balanced against thin net margins and meaningful leverage. Technicals are supportive of an uptrend, but the high P/E valuation materially caps the overall score.
Positive Factors
Revenue Growth
Sustained revenue acceleration to 38.61% in 2025 indicates expanding demand and market penetration. Over 2–6 months this supports scale advantages, higher absolute cash generation potential and provides management flexibility to reinvest in operations or service obligations, reducing execution risk.
Negative Factors
Thin Net Margins
Despite revenue and gross-margin gains, a net margin near 2.9% leaves limited earnings cushion. Structural exposure to financing, taxes or non-operating items can quickly erode profits, making long-term earnings and cash available to stakeholders vulnerable to adverse shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue acceleration to 38.61% in 2025 indicates expanding demand and market penetration. Over 2–6 months this supports scale advantages, higher absolute cash generation potential and provides management flexibility to reinvest in operations or service obligations, reducing execution risk.
Read all positive factors
Asker Healthcare Group AB (ASKER) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr29.53B
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)48.8
Beta (1Y)0.68
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees4,238
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.55
Shares Outstanding383,706,480
10 Day Avg. Volume378,678
30 Day Avg. Volume1,960,693
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)4.74
Price to Sales (P/S)1.85
P/FCF Ratio42.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr100.00Price Target Upside21.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.86
Revenue Forecast (FY)kr18.99B
Asker Healthcare Group AB Business Overview & Revenue Model
Company Description
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion s...
How the Company Makes Money
null...
Asker Healthcare Group AB Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
56
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.31B | 16.79B | 15.03B | 13.45B | 11.72B | 9.35B |
| Gross Profit | 6.65B | 6.87B | 5.88B | 4.52B | 3.78B | 2.61B |
| EBITDA | 1.60B | 2.09B | 1.47B | 1.12B | 1.12B | 670.00M |
| Net Income | 594.00M | 492.00M | 360.00M | 203.00M | 430.00M | 467.00M |
Balance Sheet | ||||||
| Total Assets | 17.75B | 16.77B | 13.12B | 11.33B | 10.23B | 7.36B |
| Cash, Cash Equivalents and Short-Term Investments | 945.00M | 884.00M | 490.00M | 391.00M | 211.00M | 494.00M |
| Total Debt | 6.02B | 5.81B | 5.96B | 4.97B | 4.74B | 3.93B |
| Total Liabilities | 10.88B | 10.19B | 9.62B | 8.29B | 7.44B | 5.54B |
| Stockholders Equity | 6.83B | 6.55B | 3.47B | 3.02B | 2.76B | 1.79B |
Cash Flow | ||||||
| Free Cash Flow | 1.02B | 738.00M | 879.00M | 901.00M | 853.00M | 258.00M |
| Operating Cash Flow | 1.64B | 1.33B | 1.23B | 1.05B | 976.00M | 382.00M |
| Investing Cash Flow | -2.27B | -2.91B | -1.46B | -783.00M | -1.86B | -843.00M |
| Financing Cash Flow | 845.00M | 2.02B | 305.00M | -83.00M | 572.00M | 619.00M |
Asker Healthcare Group AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | kr6.65B | 18.78 | 4.40% | 3.01% | -4.91% | -23.36% | |
62 Neutral | kr29.53B | 48.75 | ― | ― | ― | ― | |
60 Neutral | kr32.31B | 36.94 | ― | 0.66% | 6.86% | 148.98% | |
58 Neutral | kr12.97B | -2.59 | 3.34% | 0.80% | -5.68% | -1106.19% | |
57 Neutral | kr19.61B | 34.48 | 7.24% | 0.46% | -0.32% | 83.82% | |
53 Neutral | kr20.02B | -38.50 | 3.08% | 4.25% | -7.22% | -317.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:ASKER
Asker Healthcare Group AB
75.60
-31.74
-29.57%
SE:EKTA.B
Elekta AB
52.10
6.85
15.14%
SE:VITR
Vitrolife AB
95.90
-42.28
-30.60%
SE:MCOV.B
Medicover AB
212.50
-22.05
-9.40%
SE:ALIF.B
AddLife AB
160.70
-30.31
-15.87%
SE:ARJO.B
Arjo AB
24.20
-6.57
-21.34%
Asker Healthcare Group AB Corporate Events
Asker Healthcare starts 2026 with strong growth, margin gains and new deals
May 6, 2026
Asker Healthcare Group reported a strong first quarter of 2026, with net sales up 13% to SEK 4.52 billion and organic growth of 5%. Adjusted EBITA rose 21% with an 8% organic increase, lifting the adjusted EBITA margin to 9.8%, while profit for th...
Asker Healthcare Group Schedules Webcast for Q1 2026 Interim Report
Apr 22, 2026
Asker Healthcare Group will release its interim report for the first quarter of 2026 on 6 May and will host a webcast presentation the same day for investors, analysts and media. The online event, led by CEO Johan Falk and CFO Thomas Moss, will in...
Asker Healthcare Group Posts Strong 2025 Growth and Expands European Reach
Apr 16, 2026
Asker Healthcare Group, a European provider of medical products and solutions to healthcare systems, operates through a network of entrepreneurial local companies backed by the scale and expertise of a larger group. With more than 4,500 employees ...
Asker Healthcare Updates Share Count After Conversion of Class C Shares
Mar 31, 2026
Asker Healthcare Group has updated its share capital structure, confirming that as of 31 March 2026 it has 383,706,497 ordinary shares in issue, corresponding to the same number of votes. The company now holds 670,000 of these ordinary shares in t...
Asker Healthcare Group Calls 2026 AGM, Details Shareholder Participation Rules
Mar 30, 2026
Asker Healthcare Group AB has called its Annual General Meeting for 7 May 2026 in Stockholm, setting out procedures for shareholders to attend in person or be represented by proxy. The notice clarifies record dates, registration deadlines, and adv...
Asker Healthcare Group to Acquire Belgium’s RMS Medical Devices
Mar 20, 2026
Asker Healthcare Group, a European provider of medical products and solutions that grows through acquiring strong local healthcare companies, continues to expand its footprint in key markets. By combining entrepreneurial local operations with the ...
Asker Healthcare Issues and Reclassifies Shares to Fund Long-Term Incentive Plan
Mar 9, 2026
Asker Healthcare Group has executed a targeted share transaction to support its employee incentive structure, issuing 670,000 Class C shares, immediately repurchasing them, and reclassifying them into ordinary shares. This maneuver, carried out un...
Asker Healthcare Group Nomination Committee Proposes New Chair and Board Member for 2026
Feb 24, 2026
Asker Healthcare Group’s Nomination Committee has proposed leadership changes to the Board of Directors ahead of the 2026 AGM, putting forward former Coor chief executive and current chair Mikael Stöhr as the new Chair and board member,...
Asker Healthcare Delivers Strong 2025 on M&A-Driven Growth and Margin Gains
Feb 10, 2026
Asker Healthcare Group reported a strong 2025, with net sales rising 12% to SEK 16.8bn and adjusted EBITA up 17%, lifting the margin to 9.5% for the year and 10% in the fourth quarter. Profit and earnings per share grew sharply, cash flow from ope...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.